Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06679569
Recruiting Not applicable

Deep Neuromuscular Blockade on Postoperative Pain

NCT06679569 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Hospital
Phase
Not applicable
Started
2024-11-06
Last updated
2025-05-13

Condition(s) studied

Neuromuscular Blockade

Investigational drug(s) / intervention(s)

rocuronium 0.2 mg/kg/hr continuous infusionrocuronium 0.6 mg/kg/hr continuous infusion

rocuronium 0.2 mg/kg/hr continuous infusion: To maintain Train-of-four count 1 to 3 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.2 mg/kg/hr to achieve and sustain moderate neuromuscular blockade.

rocuronium 0.6 mg/kg/hr continuous infusion: To maintain Train-of-four count 0 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.6 mg/kg/hr to achieve and sustain deep neuromuscular blockade.

Study summary

This study aims to investigate the impact of varying degrees of neuromuscular blockade on postoperative pain in pediatric patients aged over 2 months to under 7 years undergoing laparoscopic surgery under general anesthesia.

Eligibility

Sex
ALL
Min age
2 Months
Max age
7 Years
Healthy volunteers
No
Inclusion Criteria: * Pediatric patients aged over 2 months to under 7 years scheduled for laparoscopic surgery under general anesthesia. * American Society of Anesthesiologists (ASA) Physical Status Classification I, II, or III. Exclusion Criteria: * Patients undergoing emergency surgery. * Patients with chronic pain or currently taking analgesics for chronic pain. * Known hypersensitivity to general anesthetic agents or analgesics. * Patients with underlying cardiovascular disease. * Patients with neuromuscular disorders. * Any other condition that, in the investigator's judgment, would make the patient unsuitable for participation in the study.

Primary outcome measure(s)

  • ANIm (Analgesia Nociception Index) Value — 30 minutes after arrival in the recovery room

Trial sites (1)

FacilityCityRegionStatus
SNUCH Seoul Seoul Recruiting

More Seoul National University Hospital trials in South Korea

Lung Cancer Surgery in Sarcopenia Patients With Old Age Active, not recruiting
Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION) Recruiting
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis Recruiting
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer Recruiting
Reduction of Remifentanil-related Complications Starting soon

Other trials for the same condition

Abdominal Muscle Volume and a Neuromuscular Blocking Agent Starting soon
High Dimensional Analysis of Immune Cells in Pediatric Patients Recruiting
Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06679569 on ClinicalTrials.gov ↗ ← All trials in South Korea